162 related articles for article (PubMed ID: 37536162)
1. Organogold(III)-dithiocarbamate compounds and their coordination analogues as anti-tumor and anti-leishmanial metallodrugs.
de Andrade Querino AL; de Sousa AM; Thomas SR; de Lima GM; Dittz D; Casini A; do Monte-Neto RL; Silva H
J Inorg Biochem; 2023 Oct; 247():112346. PubMed ID: 37536162
[TBL] [Abstract][Full Text] [Related]
2. Comparing the Antileishmanial Activity of Gold(I) and Gold(III) Compounds in L. amazonensis and L. braziliensis in Vitro.
Minori K; Rosa LB; Bonsignore R; Casini A; Miguel DC
ChemMedChem; 2020 Nov; 15(22):2146-2150. PubMed ID: 32830445
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability.
Gabbiani C; Casini A; Kelter G; Cocco F; Cinellu MA; Fiebig HH; Messori L
Metallomics; 2011 Dec; 3(12):1318-23. PubMed ID: 21887452
[TBL] [Abstract][Full Text] [Related]
4. Novel gold(I) complexes with 5-phenyl-1,3,4-oxadiazole-2-thione and phosphine as potential anticancer and antileishmanial agents.
Chaves JDS; Tunes LG; de J Franco CH; Francisco TM; Corrêa CC; Murta SMF; Monte-Neto RL; Silva H; Fontes APS; de Almeida MV
Eur J Med Chem; 2017 Feb; 127():727-739. PubMed ID: 27823888
[TBL] [Abstract][Full Text] [Related]
5. Proteasome versus Thioredoxin Reductase Competition as Possible Biological Targets in Antitumor Mixed Thiolate-Dithiocarbamate Gold(III) Complexes.
Quero J; Cabello S; Fuertes T; Mármol I; Laplaza R; Polo V; Gimeno MC; Rodriguez-Yoldi MJ; Cerrada E
Inorg Chem; 2018 Sep; 57(17):10832-10845. PubMed ID: 30117739
[TBL] [Abstract][Full Text] [Related]
6. A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts.
Milacic V; Chen D; Ronconi L; Landis-Piwowar KR; Fregona D; Dou QP
Cancer Res; 2006 Nov; 66(21):10478-86. PubMed ID: 17079469
[TBL] [Abstract][Full Text] [Related]
7. Insights into the reactivity of gold-dithiocarbamato anticancer agents toward model biomolecules by using multinuclear NMR spectroscopy.
Boscutti G; Marchiò L; Ronconi L; Fregona D
Chemistry; 2013 Sep; 19(40):13428-36. PubMed ID: 24038383
[TBL] [Abstract][Full Text] [Related]
8. Gold(III) Complexes for Antitumor Applications: An Overview.
Bertrand B; Williams MRM; Bochmann M
Chemistry; 2018 Aug; 24(46):11840-11851. PubMed ID: 29575433
[TBL] [Abstract][Full Text] [Related]
9. A golden future in medicinal inorganic chemistry: the promise of anticancer gold organometallic compounds.
Bertrand B; Casini A
Dalton Trans; 2014 Mar; 43(11):4209-19. PubMed ID: 24225667
[TBL] [Abstract][Full Text] [Related]
10. Stable anticancer gold(III)-porphyrin complexes: effects of porphyrin structure.
Sun RW; Li CK; Ma DL; Yan JJ; Lok CN; Leung CH; Zhu N; Che CM
Chemistry; 2010 Mar; 16(10):3097-113. PubMed ID: 20162647
[TBL] [Abstract][Full Text] [Related]
11. Rational design of gold(III)-dithiocarbamato peptidomimetics for the targeted anticancer chemotherapy.
Kouodom MN; Boscutti G; Celegato M; Crisma M; Sitran S; Aldinucci D; Formaggio F; Ronconi L; Fregona D
J Inorg Biochem; 2012 Dec; 117():248-60. PubMed ID: 22877925
[TBL] [Abstract][Full Text] [Related]
12. New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status.
Altaf M; Monim-Ul-Mehboob M; Kawde AN; Corona G; Larcher R; Ogasawara M; Casagrande N; Celegato M; Borghese C; Siddik ZH; Aldinucci D; Isab AA
Oncotarget; 2017 Jan; 8(1):490-505. PubMed ID: 27888799
[TBL] [Abstract][Full Text] [Related]
13. Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand.
Maiore L; Cinellu MA; Michelucci E; Moneti G; Nobili S; Landini I; Mini E; Guerri A; Gabbiani C; Messori L
J Inorg Biochem; 2011 Mar; 105(3):348-55. PubMed ID: 21421122
[TBL] [Abstract][Full Text] [Related]
14. Comparative biological evaluation and G-quadruplex interaction studies of two new families of organometallic gold(I) complexes featuring N-heterocyclic carbene and alkynyl ligands.
Meier-Menches SM; Aikman B; Döllerer D; Klooster WT; Coles SJ; Santi N; Luk L; Casini A; Bonsignore R
J Inorg Biochem; 2020 Jan; 202():110844. PubMed ID: 31739113
[TBL] [Abstract][Full Text] [Related]
15. Phosphine-gold(I) compounds as anticancer agents: general description and mechanisms of action.
Lima JC; Rodriguez L
Anticancer Agents Med Chem; 2011 Dec; 11(10):921-8. PubMed ID: 21864238
[TBL] [Abstract][Full Text] [Related]
16. Organogold(III) compounds as experimental anticancer agents: chemical and biological profiles.
Massai L; Cirri D; Michelucci E; Bartoli G; Guerri A; Cinellu MA; Cocco F; Gabbiani C; Messori L
Biometals; 2016 Oct; 29(5):863-72. PubMed ID: 27476157
[TBL] [Abstract][Full Text] [Related]
17. Iminophosphorane-organogold(III) complexes induce cell death through mitochondrial ROS production.
Vela L; Contel M; Palomera L; Azaceta G; Marzo I
J Inorg Biochem; 2011 Oct; 105(10):1306-13. PubMed ID: 21864808
[TBL] [Abstract][Full Text] [Related]
18. Anticancer cyclometalated [Au(III)m(C(wedge)N(wedge)C)mL]n+ compounds: Synthesis and cytotoxic properties.
Li CK; Sun RW; Kui SC; Zhu N; Che CM
Chemistry; 2006 Jul; 12(20):5253-66. PubMed ID: 16642532
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of Pyrazine-Based Cyclometalated (C^N
Bertrand B; Fernandez-Cestau J; Angulo J; Cominetti MMD; Waller ZAE; Searcey M; O'Connell MA; Bochmann M
Inorg Chem; 2017 May; 56(10):5728-5740. PubMed ID: 28441013
[TBL] [Abstract][Full Text] [Related]
20. Potential of Gold Candidates against Human Colon Cancer.
Abbasi M; Yaqoob M; Haque RA; Iqbal MA
Mini Rev Med Chem; 2021; 21(1):69-78. PubMed ID: 32767935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
